Traumatic Brain Injury Biomarkers Market Size, Share, and Trends Report by Product Category

 The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.

What Is the Current Market Size and Growth Rate of the Travel Vaccines Market?
The traumatic brain injury biomarkers market size has grown exponentially in recent years. It will grow from $1.38 billion in 2025 to $1.68 billion in 2026 at a compound annual growth rate (CAGR) of 21.9%. The growth in the historic period can be attributed to limited availability of standardized tbi biomarkers, reliance on conventional imaging techniques, growing awareness of traumatic brain injury impacts, increasing hospital-based diagnostic facilities, early research on protein and genetic biomarkers.

The traumatic brain injury biomarkers market size is expected to see exponential growth in the next few years. It will grow to $3.68 billion in 2030 at a compound annual growth rate (CAGR) of 21.6%. The growth in the forecast period can be attributed to advancement in high-sensitivity protein and genetic assays, integration of metabolomic biomarkers in tbi assessment, growth of personalized monitoring and prognosis tools, expansion of hospital and diagnostic lab adoption, rising investment in tbi biomarker research and clinical trials. Major trends in the forecast period include increased adoption of blood-based and csf-based biomarker testing, rising focus on early diagnosis and prognosis of traumatic brain injury, development of multiplex protein and genetic biomarker panels, expansion of monitoring tools for treatment response, integration of research-based biomarkers into clinical practice.

Claim your free report sample now:
https://www.thebusinessresearchcompany.com/report/traumatic-brain-injury-biomarkers-global-market-report

What Are the Leading Growth Factors in the Traumatic Brain Injury Biomarkers Market?
The increasing number of road traffic accidents is expected to propel the growth of the traumatic brain injury biomarkers market going forward. Road traffic accidents refer to unplanned, unexpected events that cause injury, harm, or damage, often requiring immediate medical attention. The number of road traffic accidents is rising due to a rapid increase in private vehicle usage due to urbanization and motorization. Traumatic brain injury biomarkers aid in road traffic accident care by enabling rapid and accurate assessment of head injuries. They support early diagnosis by detecting specific proteins in the blood, helping clinicians make timely treatment decisions and improving patient outcomes in emergency situations. For instance, in October 2025, according to a report published by the National Highway Traffic Safety Administration (NHTSA), a US-based national safety organisation, reported that the United States recorded 6,138,359 police-reported motor-vehicle crashes, resulting in 40,901 deaths and 2,442,581 injuries, highlighting a significant trauma burden. Therefore, the increasing number of road traffic accidents is driving the growth of the traumatic brain injury biomarkers market.

What Are the Key Segment Classifications in the Traumatic Brain Injury Biomarkers Market?
The traumatic brain injury biomarkers market covered in this report is segmented –

1) By Type: Protein Biomarkers, Genetic Biomarkers, Metabolomic Biomarkers
2) By Sample Type: Blood-based, Cerebrospinal Fluid (CSF)-Based, Urine-Based
3) By Application: Diagnosis, Prognosis, Monitoring Treatment Response
4) By End Use: Hospitals And Clinics, Diagnostic Laboratories, Research Institutes

Subsegments:
1) By Protein Biomarkers: Glial Fibrillary Acidic Protein (GFAP), Ubiquitin C-Terminal Hydrolase L1 (UCH-L1), S100 Calcium Binding Protein B (S100B), Neuron-Specific Enolase (NSE)
2) By Genetic Biomarkers: Apolipoprotein E (APOE) Genotyping, Brain-Derived Neurotrophic Factor (BDNF) Polymorphism, Interleukin-6 (IL-6) Gene Variants, Tumor Necrosis Factor-Alpha (TNF-α) Polymorphism
3) By Metabolomic Biomarkers: Lactate, Creatine, Choline, N-Acetylaspartate (NAA)

What Are the Key Trends Shaping the Traumatic Brain Injury Biomarkers Market?
Major companies operating in the traumatic brain injury biomarker market are focusing on developing innovative solutions, such as a laboratory-based blood test, to improve the accuracy and speed of concussion evaluation and diagnosis. A laboratory-based blood test is a diagnostic tool that measures specific biomarkers in the blood to assess the presence and severity of brain injuries, enabling earlier and more objective clinical decisions. For instance, in June 2025, Abbott Laboratories, a US-based healthcare company, launched the Alinity i and Architect i1000SR lab tests. These tests measure two key biomarkers, glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase (UCH)-L1, to help clinicians evaluate suspected concussions within 12 hours of injury. These also deliver lab results in just 18 minutes, support faster triage decisions in emergency settings, and reduce reliance on unnecessary CT scans. This innovation provides physicians with a reliable method for identifying patients with potential traumatic brain injuries. It also represents a significant advancement in expanding access to faster, evidence-based care in emergency departments.

Which Are the Top Companies in the Traumatic Brain Injury Biomarkers Market?
Major companies operating in the traumatic brain injury biomarkers market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, BioMérieux S.A., DiaSorin S.p.A., Abcam Limited, Fujirebio Inc., Meso Scale Diagnostics (MSD), Olink Holding AB, Quanterix Corporation, OriGene Technologies Inc., BioDirection Inc., BrainBox Solutions Inc., NeuroTrauma Sciences LLC, Banyan Biomarkers Inc.

Get the full traumatic brain injury biomarkers market report here:
https://www.thebusinessresearchcompany.com/report/traumatic-brain-injury-biomarkers-global-market-report

Which regions are expected to experience the fastest growth in the Traumatic Brain Injury Biomarkers Market?
North America was the largest region in the traumatic brain injury biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the traumatic brain injury biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: Global Market Research Reports & Consulting | The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: The Business Research Company | LinkedIn